Schrödinger

120 West 45th Street
17th Floor
New York
NY
10036-4041
United States

Tel: 503-299-1150

Website: https://www.schrodinger.com/careers

About Schrödinger

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a co-founder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science.

A great company is made up of great people, and Schrödinger is no exception. Whether you’re in Administration, Sales, Finance, Law, Engineering, IT, or Science, we are always on the lookout for exceptional candidates who can join us and make our team stronger. You will find Schrödinger to be a dynamic, energetic, and fast-paced place to work, where you get to interact with some of the smartest and hardest working people you’ll ever meet. If you’ve ever had a curiosity about science, and how science can improve people’s lives, then there’s no
better place to be than Schrödinger.

Stock Exchange: NASDAQ

Stock Symbol: SDGR

58 articles with Schrödinger

Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

12/7/2020

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology Annual Meeting.
Schrödinger, Inc. Reports Third Quarter 2020 Financial Results and Business Update

11/12/2020

Total revenue of $25.8 million, up 29% year-over-year; Software revenue of $22.9 million, up 42% year-over-year Raised $325.6 million net proceeds in equity financing Presenting data on our MALT 1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting & Exposition Conference call today, Thursday, Nov. 12, 2020 at 8:30 a.m. ET
Schrödinger to Present at Upcoming Investor Conferences - Nov 10, 2020

11/10/2020

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that members of the management team will participate in the upcoming virtual investor conferences in November and December.
Schrödinger to Present Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

11/5/2020

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced it will present data from its preclinical MALT1 inhibitor program at the 62nd American Society of Hematology Annual Meeting and Exposition to be held virtually December 5-8, 2020.
Schrödinger to Host Third Quarter 2020 Financial Results Conference Call and Webcast

11/5/2020

Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 a.m. ET to discuss third quarter 2020 financial results and provide a general business update.
Schrödinger to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

9/8/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 p.m. ET on Tuesday, September 15, 2020.
Schrödinger Announces Closing of Public Offering - Aug 17, 2020

8/17/2020

Schrödinger, Inc., whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, announced the closing of its underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $66.00 per share.
Schrödinger Announces Pricing of Public Offering - Aug 13, 2020

8/13/2020

Schrödinger, Inc., whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $66.00 per share.
Schrödinger, Inc. Reports Second Quarter 2020 Financial Results and Business Updates

8/10/2020

Schrödinger, Inc., whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced financial results for the second quarter ended June 30, 2020.
Schrödinger to Host Second Quarter 2020 Financial Results Conference Call and Webcast

8/3/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that it will host a conference call and webcast on Monday, August 10, 2020 at 8:30 a.m. ET to discuss second quarter 2020 financial results and provide a general business update.
Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

7/28/2020

Collaboration aims to enable discovery of first-in-class therapeutic candidates
Schrödinger Expands Discovery Efforts for COVID-19 Alliance with Advanced Molecular Simulation Leveraging High-Powered Parallel Computing on Google Cloud

6/23/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced a significant expansion of its work to discover novel antiviral therapeutics for COVID-19 as a part of a philanthropic global initiative.
Schrödinger Announces Strategic Collaboration With Thermo Fisher Scientific to Expand Structure-Based Drug Discovery to Novel Targets Using Cryo-EM

6/23/2020

Schrödinger announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery.
Schrödinger to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

6/16/2020

Schrödinger (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, today announced that members of the management team will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference at 2:30 p.m. ET on Tuesday, June 23, 2020. A live webcast of the presentation can be accessed under "News & Events" in th
Schrödinger to Present at the Jefferies 2020 Virtual Healthcare Conference

5/28/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that members of the management team will participate in a fireside chat at the Jefferies 2020 Virtual Healthcare Conference at 3:00 p.m. ET on Thursday, June 4, 2020.
Schrödinger Reports First Quarter 2020 Financial Results and Recent Business Updates

5/13/2020

Total revenue of $26.2 million and strong growth of 26% year-over-year Record software revenue of $23.8 million, up 28% year-over-year Raised $209.6 million in net proceeds through initial public offering Conference call today, Wednesday, May 13, 2020 at 8:30 a.m. ET NEW YORK--( BUSINESS WIRE )-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform enables discovery of high-quality, novel molecules for therapeu
BioSpace Movers & Shakers, May 8

5/8/2020

Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Schrödinger to Host First Quarter 2020 Financial Results Conference Call and Webcast

5/6/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that it will host a conference call and webcast on Wednesday, May 13, 2020 at 8:30 a.m. ET to discuss first quarter 2020 financial results and provide a general business update.
Schrödinger Strengthens Board of Directors with Appointments of Jeffrey Chodakewitz, M.D., and Gary Ginsberg

5/4/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced the appointments of Jeffrey A. Chodakewitz, M.D., and Gary Ginsberg to its Board of Directors.
Schrödinger Announces Expanded Collaboration with AstraZeneca to Extend Computational Modeling Solutions to Biologics

3/23/2020

Schrödinger announced an expanded collaboration with AstraZeneca focused on refining a biologics modeling solution with the aim of speeding up the development of antibody and protein-based therapeutic candidates.